Post Subject #44   JP Morgan webcast https://jpmorgan.metameetings.net/events/healthcare21/sessions jondoeuk 01/20/21 10:22:17 PM #43   SITC posters: jondoeuk 11/10/20 04:29:52 PM #42   Updated corporate presentation (RP1 & RP2 data) https://ir.replimune.com/static- jondoeuk 10/22/20 02:11:53 PM #41   SITC Title: (650) An Open-label, multicenter, Phase 1/2 clinical jondoeuk 10/14/20 01:16:51 PM #40   Slides from the IO Summit (the company isn't jondoeuk 10/07/20 06:41:37 PM #39   Slides from the event https://ir.replimune.com/static-files/def39b44-9f58-4fbd-8a36-2f96f628519a jondoeuk 06/24/20 05:45:38 PM #38   The company will host a conference call to jondoeuk 06/01/20 01:14:21 PM #37   Looks good https://meetinglibrary.asco.org/record/192615/abstract jondoeuk 05/15/20 09:13:09 PM #36   Initial data on RP2 could be presented at SITC. jondoeuk 05/02/20 06:55:20 PM #35   Two new trials listed. The first is a jondoeuk 05/02/20 02:28:22 PM #34   Small number, but encouraging data on another 'armed' jondoeuk 04/22/20 09:09:19 PM #33   An update from last month https://ir.replimune.com/static-files/7aa0f042-b0cf-4f jondoeuk 02/19/20 07:10:25 PM #32   J.P. Morgan webcast https://jpmorgan.metameetings.net/events/hc20/sessions/29931 jondoeuk 01/26/20 03:09:48 PM #31   The company has appointed Jean M. Franchi as jondoeuk 12/09/19 04:06:52 PM #30   Piper Jaffray slides https://ir.replimune.com/static-files/023a7710-3ec0-4f57-a7 jondoeuk 12/08/19 01:33:12 PM #29   So the company will raise ~$80M with this jondoeuk 11/16/19 12:49:24 PM #28   The PR https://markets.businessinsider.com/news/stocks/replimune-presents-initia jondoeuk 11/08/19 11:34:44 AM #27   The company will host an investor event to jondoeuk 11/03/19 03:23:18 PM #26   Finally the RP2 trial starts! jondoeuk 10/24/19 04:49:43 PM #25   I did not expect this data [1,2]. It's jondoeuk 10/15/19 11:57:20 AM #24   SITC title (P433) Initial results of the phase jondoeuk 10/01/19 06:24:15 PM #23   It is finally recruiting. Clock starts now. jondoeuk 09/15/19 07:22:11 PM #22   An update (of sorts) on the company's manufacturing jondoeuk 08/31/19 02:13:06 PM #21   A new preclinical paper https://jitc.biomedcentral.com/articles/10.1186/s40425-0 jondoeuk 08/12/19 11:51:47 AM #20   The randomised trial has been added https://clinicaltrials.gov/ct2/show/NCT04050 jondoeuk 08/08/19 03:24:39 PM #19   I've searched for titles at the ESMO website jondoeuk 08/06/19 04:42:55 PM #18   After reading the 10-k initial study site activation jondoeuk 06/29/19 02:25:33 PM #17   Has anyone emailed IR? jondoeuk 06/19/19 06:19:39 PM #16   Here is the poster (PDF for those that jondoeuk 06/02/19 06:46:00 PM #15   Here is the link https://meetinglibrary.asco.org/record/176374/abstract jondoeuk 05/09/19 10:32:32 AM #14   ASCO title (abstract TPS2671): An open label, multicenter, jondoeuk 04/17/19 01:33:38 PM #13   In the pivotal PhIII trial of ipilimumab, Grade jondoeuk 04/07/19 04:01:56 PM #12   Nice poster and presentation. Thanks. For RP2 and avav1001 04/06/19 03:35:02 PM #11   Here is a link to the AACR poster https://ir.replimune.com/static-files/c14ef41a jondoeuk 04/02/19 05:02:48 PM #10   Today or tomorrow Openreach will be carrying out jondoeuk 03/17/19 08:45:41 PM #9   AACR: Development & characterization of a new oncolytic jondoeuk 02/27/19 05:13:50 PM #8   Here is the paper https://www.journalacs.org/article/S1072-7515(19)30024-9/fullt jondoeuk 02/07/19 05:06:40 PM #7   I just came across this (Imlygic) https://www.medicalnewstoday.com/articles/3242 jondoeuk 01/29/19 05:36:18 PM #6   This is a link to the J.P. Morgan jondoeuk 01/10/19 08:14:53 PM #5   I was hoping RP3 would be 'armed' with jondoeuk 01/03/19 02:39:53 PM #4   Here is a link to the webcast https://jpmorgan.metameetings.net/events/healthcar jondoeuk 12/31/18 06:43:11 PM #3   Talk about a haircut! jondoeuk 12/29/18 03:45:06 PM #2   The competition comes 'armed' https://www.businesswire.com/news/home/201811280 jondoeuk 12/02/18 03:50:03 PM #1   Does anyone have the slides from the presentation jondoeuk 10/19/18 03:12:11 PM Post Subject

© 2021 InvestorsHub.com, Inc.